Literature DB >> 19685005

Function and regulation of Dyrk1A: towards understanding Down syndrome.

Joongkyu Park1, Woo-Joo Song, Kwang Chul Chung.   

Abstract

Down syndrome (DS) is associated with a variety of symptoms, such as incapacitating mental retardation and neurodegeneration (i.e., Alzheimer's disease), that prevent patients from leading fully independent lives. These phenotypes are a direct consequence of the overexpression of chromosome 21 genes, which are present in duplicate due to non-disjunction of chromosome 21. Accumulating data suggest that the chromosome 21 gene product, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (Dyrk1A), participates in the pathogenic mechanisms underlying the mental and other physical symptoms of DS. In this review, we summarize the evidence supporting a role for Dyrk1A in DS, especially DS pathogenesis. Recently, several natural and synthetic compounds have been identified as Dyrk1A inhibitors. Understanding the function and regulation of Dyrk1A may lead to the development of novel therapeutic agents aimed at treating DS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19685005     DOI: 10.1007/s00018-009-0123-2

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  69 in total

1.  Aggressive behaviour associated with donepezil treatment: a case report.

Authors:  Angelo Bianchetti; Marco Trabucchi; Giovanna Cipriani
Journal:  Int J Geriatr Psychiatry       Date:  2003-07       Impact factor: 3.485

2.  Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome.

Authors:  Z Rahmani; J L Blouin; N Creau-Goldberg; P C Watkins; J F Mattei; M Poissonnier; M Prieur; Z Chettouh; A Nicole; A Aurias
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

3.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.

Authors:  Yousang Gwack; Sonia Sharma; Julie Nardone; Bogdan Tanasa; Alina Iuga; Sonal Srikanth; Heidi Okamura; Diana Bolton; Stefan Feske; Patrick G Hogan; Anjana Rao
Journal:  Nature       Date:  2006-03-01       Impact factor: 49.962

4.  Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.

Authors:  X Altafaj; M Dierssen; C Baamonde; E Martí; J Visa; J Guimerà; M Oset; J R González; J Flórez; C Fillat; X Estivill
Journal:  Hum Mol Genet       Date:  2001-09-01       Impact factor: 6.150

5.  Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation.

Authors:  Eun Joo Kim; Jee Young Sung; Hyun Jung Lee; Hyewhon Rhim; Masato Hasegawa; Takeshi Iwatsubo; Do Sik Min; Jongsun Kim; Seung R Paik; Kwang Chul Chung
Journal:  J Biol Chem       Date:  2006-09-07       Impact factor: 5.157

6.  Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice.

Authors:  Lisa E Olson; Randall J Roper; Crystal L Sengstaken; Elizabeth A Peterson; Veronica Aquino; Zygmunt Galdzicki; Richard Siarey; Mikhail Pletnikov; Timothy H Moran; Roger H Reeves
Journal:  Hum Mol Genet       Date:  2007-03-05       Impact factor: 6.150

7.  The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development.

Authors:  Ariadna Laguna; Sergi Aranda; María José Barallobre; Rima Barhoum; Eduardo Fernández; Vassiliki Fotaki; Jean Maurice Delabar; Susana de la Luna; Pedro de la Villa; Maria L Arbonés
Journal:  Dev Cell       Date:  2008-12       Impact factor: 12.270

8.  Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated.

Authors:  D P Hanger; J P Brion; J M Gallo; N J Cairns; P J Luthert; B H Anderton
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

9.  Molecular genetic approach to the characterization of the "Down syndrome region" of chromosome 21.

Authors:  M K McCormick; A Schinzel; M B Petersen; G Stetten; D J Driscoll; E S Cantu; L Tranebjaerg; M Mikkelsen; P C Watkins; S E Antonarakis
Journal:  Genomics       Date:  1989-08       Impact factor: 5.736

10.  Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A.

Authors:  Fayçal Guedj; Catherine Sébrié; Isabelle Rivals; Aurelie Ledru; Evelyne Paly; Jean C Bizot; Desmond Smith; Edward Rubin; Brigitte Gillet; Mariona Arbones; Jean M Delabar
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

View more
  82 in total

Review 1.  Trisomy 21 and early brain development.

Authors:  Tarik F Haydar; Roger H Reeves
Journal:  Trends Neurosci       Date:  2011-12-09       Impact factor: 13.837

Review 2.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

3.  Expression of the DYRK1A gene correlates with its 3D positioning in the interphase nucleus of Down syndrome cells.

Authors:  Nerea Paz; Izaskun Felipe-Blanco; Félix Royo; Amaia Zabala; Isabel Guerra-Merino; África García-Orad; José L Zugaza; Luis A Parada
Journal:  Chromosome Res       Date:  2015-02-03       Impact factor: 5.239

4.  Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.

Authors:  Karol Dowjat; Tatyana Adayev; Wojciech Kaczmarski; Jerzy Wegiel; Yu-Wen Hwang
Journal:  J Neuropathol Exp Neurol       Date:  2012-12       Impact factor: 3.685

5.  Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of the Wnt signaling pathway.

Authors:  Ji Yeon Hong; Jae-Il Park; Moonsup Lee; William A Muñoz; Rachel K Miller; Hong Ji; Dongmin Gu; Jerome Ezan; Sergei Y Sokol; Pierre D McCrea
Journal:  J Cell Sci       Date:  2012-02-01       Impact factor: 5.285

6.  Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle.

Authors:  Jia-Yun Chen; Jia-Ren Lin; Feng-Chiao Tsai; Tobias Meyer
Journal:  Mol Cell       Date:  2013-10-10       Impact factor: 17.970

Review 7.  Using C. elegans to decipher the cellular and molecular mechanisms underlying neurodevelopmental disorders.

Authors:  Carlos Bessa; Patrícia Maciel; Ana João Rodrigues
Journal:  Mol Neurobiol       Date:  2013-03-14       Impact factor: 5.590

8.  Development of a sensitive non-radioactive protein kinase assay and its application for detecting DYRK activity in Xenopus laevis oocytes.

Authors:  Eva Lilienthal; Katharina Kolanowski; Walter Becker
Journal:  BMC Biochem       Date:  2010-05-20       Impact factor: 4.059

9.  Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome.

Authors:  Chelsee A Hewitt; King-Hwa Ling; Tobias D Merson; Ken M Simpson; Matthew E Ritchie; Sarah L King; Melanie A Pritchard; Gordon K Smyth; Tim Thomas; Hamish S Scott; Anne K Voss
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

10.  C. elegans SWAN-1 Binds to EGL-9 and regulates HIF-1-mediated resistance to the bacterial pathogen Pseudomonas aeruginosa PAO1.

Authors:  Zhiyong Shao; Yi Zhang; Qi Ye; Jenifer Neeta Saldanha; Jo Anne Powell-Coffman
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.